Navigation Links
Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
Date:11/20/2007

ard-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the respective Phase II clinical trials for Amigal(TM) and Plicera(TM), and the Phase I clinical trial for AT2220 may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. All forward- looking statements are qualified in their entirety by this cautionary statement and Amicus undertakes no obligation to revise or update this news release to reflect events or
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 30, 2015  The University of California, San ... and UC San Diego Extension announced their third ... Aug.  12 – 14, 2015, at UC San ... provides an intense exposure to best practices and ... well-suited to biologists, process engineers and business executives ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... first participant in its Phase 1/2 clinical trial ... chronic unilateral Achilles tendinosis, has been enrolled and ... intra-tendon ultrasound-guided injections. RCT-01 is comprised of non-bulbar ...
(Date:6/30/2015)... ... June 30, 2015 , ... Southern ... accepted the position of vice president of instruction at Chippewa Valley Technical College ... greatly appreciated the opportunity to lead SIUE during the past three years,” Furst-Bowe ...
(Date:6/30/2015)... Florida (PRWEB) , ... June 30, 2015 , ... ... cannabis digital media company, launched “Cannavoices,” an unprecedented digital video and broadcast ... largest but also the most dynamic collection of legal medical cannabis stories ever ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading,international pharmaceutical ... 31, 2007., 2007 Full Year Financial Highlights:, - ... in 2006 - Chemical Division,s ... $45.8 million in 2006. ...
... 31 NxStage Medical,Inc. (Nasdaq: NXTM ), ... that Tom Shea has joined the Company as ... 2008. Mr.,Shea will be responsible for all of ... Mr. Shea joins NxStage with more than ...
... MANASQUAN, NJ., March 31 BioSpace, the world,s leading,online ... will host,the Biotech Beach(TM) Career in La Jolla, CA ... at the Hyatt Regency La Jolla from 2 pm-7 ... science professionals from across Southern California will attend,the biotech ...
Cached Biology Technology:Dragon Pharma announces 2007 full year financial results 2Dragon Pharma announces 2007 full year financial results 3Dragon Pharma announces 2007 full year financial results 4Dragon Pharma announces 2007 full year financial results 5Dragon Pharma announces 2007 full year financial results 6Dragon Pharma announces 2007 full year financial results 7NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 2NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 3Bioscience Career Fair in San Diego Expected to Draw Record Jobseeker Attendance 2
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/23/2015)...   Valencell, a leader in performance ... recent study that illustrates its PerformTek biometric technology ... In a study conducted at Valencell,s Biometric Lab, ... Apple Watch against a chest strap – the ... The study demonstrated that Valencell,s biometric technology delivers ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... (June 28 2013) A study carried out in India ... bone marrow stem cells in patients with type 2 ... when compared to a control group of TD2M patients ... , The study appears as an early e-publication for ...
... make a big difference. A "left-handed" molecule of a ... its mirror-image "right-handed" counterpart could be completely inactive. That,s ... crucial: Living organisms are made only from left-handed amino ... Now, a team of scientists at the U.S. ...
... the late spring, the 4000 elk of the Clarks ... following the greening grass into the highlands of the ... on vegetation fed by snowmelt. It,s a short trip ... uncommonly free of roads, fences, metropolitan areas, and other ...
Cached Biology News:Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use 2Tiny nanocubes help scientists tell left from right 2Tiny nanocubes help scientists tell left from right 3Declining fortunes of Yellowstone's migratory elk 2Declining fortunes of Yellowstone's migratory elk 3Declining fortunes of Yellowstone's migratory elk 4
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Rabbit polyclonal antibody to GluR2...
... Blocker Array II can be used to ... various proteins and sera that are commonly ... The array contains spots for 19 different ... Determination of antibody crossreactivity and species specificity, ...
... sufficient materials for 1,464 array sample elements. , ... , Blocker BSA in PBS (10X): 50 ... 10 g , BupH Phosphate Buffered ... 2 x 10 ml ampules , SuperSignal West ...
Biology Products: